Navigation Links
Questcor Pharmaceuticals Reports Strong Finish to 2011
Date:1/6/2012

e preliminary and subject to change.  Questcor currently expects to release audited results for the fourth quarter and full year on February 22, 2012.

Additional Notes

  1. The Company's quarterly vial shipments continue to be subject to significant variation due to the size and timing of individual orders received from Questcor's distributor, and the timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter.  For this reason, as well as other factors causing quarter-to-quarter variability in Questcor's operating results, the Company believes that investors should consider the Company's results over several quarters when analyzing the Company's performance.
  2. Because Acthar prescriptions are filled at specialty pharmacies, the Company does not receive complete information regarding either the number of prescriptions or the number of vials by therapeutic area for all of the patients being treated with Acthar. However, Questcor is able to monitor trends in payer mix and areas of therapeutic use for new, paid Acthar prescriptions based on data it receives from its reimbursement support center. Questcor estimates that over 90% of new, paid Acthar prescriptions are processed by this support center, but believes that very few refill prescriptions are processed there.
  3. Effective December 27, 2011, the Company increased the price of Acthar by a nominal amount.

 

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indica
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
2. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
3. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
4. Questcor Reports Third Quarter Financial Results
5. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
6. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
7. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
8. Questcor Provides Updated New Paid Prescription Trends
9. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... 2011 Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... unit, SAFC® ( www.safcglobal.com ), is introducing a novel ... (CHO) cell line. Designed for use in the production ... the first commercially available glutamine synthetase (GS) knockout CHO ...
... YORK, Oct. 27, 2011 Reportlinker.com ... report is available in its catalogue: ... Reimbursement Outlook: Optimizing price and market ... http://www.reportlinker.com/p0165652/Pharma-Pricing-and-Reimbursement-Outlook-Optimizing-price-and-market-access-in-a-recessionary-climate.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Health_Insurance ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 2Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 3Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 5
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... that teaches readers how they can use natural methods ... for years has caught the attention of Shane Michaels, ... only a condition that affects the skin, it can ... suffer from it,” reports Michaels. “The intense itching and ...
(Date:8/22/2014)... receptor (EGFR) mutations found in the circulating free tumor ... lung cancer (NSCLC) patients correlates well with the EGFR ... kinase inhibitor (TKI) therapy is approved for EGFR activating ... for determining mutation status is with DNA derived directly ... available. A more abundant and less invasive source of ...
(Date:8/22/2014)... Advancements in ultrasound technologies make ... due to their cost-effectiveness, non-invasiveness, and absence of ... such as the evolution of wireless transducers and ... market moving throughout 2014 and beyond. Such Ultrasound’s ... only the point-of-care (POC) testing in hospital settings, ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
(Date:8/22/2014)... West Orange, NJ. August 22, 2014. A ... shows that persons with multiple sclerosis (MS) may ... cognitive rehabilitation. The study was epublished ahead of ... (Yael Goverover, Helen Genova, Hali Griswold, Nancy D. ... awareness in persons with multiple sclerosis doi: 10.3233/NRE-141113). ...
Breaking Medicine News(10 mins):Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... for study of human genetics and disease , THURSDAY, Aug. ... genes are responsible for all seven types of coats found ... like Bo, President Obama,s pooch, or long-haired like Lassie, variations ... to a U.S. National Institutes of Health study published online ...
... disparity in prostate cancer stage at diagnosis has decreased ... published online August 27 in the Journal of ... from the Surveillance, Epidemiology, and End Results (SEER) program, ... New Jersey and the University of Medicine and Dentistry ...
... RICHMOND, Va., Aug. 27 The ,Help is Here ... week of August 31 - September 3 at various cities ... on programs that provide prescription medicines for free or nearly ... - and having risen for 26 straight months - the ...
... ,fatostatin, is still in early stages , THURSDAY, Aug. 27 ... to have the power to turn off fat production, potentially ... injected with the chemical, known as fatostatin, didn,t get fatter ... team said. , But don,t run out and ask ...
... , MINNEAPOLIS, Aug. 27 In August 1989, a ... to become one of the first child advocacy centers in the ... organization, improving the way child abuse is investigated around the world. ... medical examinations for children and vulnerable adults who report sexual abuse ...
... The Radiological Society of North America (RSNA) reaffirmed ... a study and accompanying perspective on radiation dose from ... of Medicine (NEJM). In "Exposure to ... M.D., M.Sc., and colleagues reported that imaging procedures are ...
Cached Medicine News:Health News:Benji, Marley or Bo: Three Genes Dictate Dog's Coat 2Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 4Health News:Fat-Fighting Chemical Holds Promise 2Health News:Minneapolis-based CornerHouse Marks 20th Anniversary of Helping Sexually Abused Children Around the World 2Health News:Minneapolis-based CornerHouse Marks 20th Anniversary of Helping Sexually Abused Children Around the World 3Health News:Radiologists, medical physicists work to make imaging procedures safer 2
... The 1081 is an all-in-one drape ... The drape includes a pouch with filter ... finger cot. 64 inches (164cm) TUR ... Elastic aperture, Neoprene finger cot, Fluid collection ...
... Both the Penilab IV and the Penilab V ... studies. Model 1060 is similar to the Model ... nor can one be added later. The Penilab ... including all of the accessories you'll need to get ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
Medicine Products: